Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Semin Nucl Med. 2019 Sep;49(5):339-356. doi: 10.1053/j.semnuclmed.2019.07.001. Epub 2019 Jul 20.
This review describes general concepts with regard to radiopharmaceuticals for diagnostic or therapeutic applications that help to understand the specific challenges encountered during the design, (radio)synthesis, in vitro and in vivo evaluation and clinical translation of novel radiopharmaceuticals. The design of a radiopharmaceutical requires upfront decisions with regard to combining a suitable vector molecule with an appropriate radionuclide, considering the type and location of the molecular target, the desired application, and the time constraints imposed by the relatively short half-life of radionuclides. Well-designed in vitro and in vivo experiments allow nonclinical validation of radiotracers. Ultimately, in combination with a limited toxicology package, the radiotracer becomes a radiopharmaceutical for clinical evaluation, produced in compliance with regulatory requirements for medicines for intravenous (IV) injection.
本综述描述了用于诊断或治疗应用的放射性药物的一般概念,有助于理解在新型放射性药物的设计、(放射性)合成、体外和体内评估以及临床转化过程中遇到的具体挑战。放射性药物的设计需要在将合适的载体分子与适当的放射性核素结合方面做出预先决策,同时考虑分子靶标类型和位置、预期应用以及放射性核素相对较短半衰期所带来的时间限制。精心设计的体外和体内实验可对放射性示踪剂进行非临床验证。最终,放射性示踪剂与有限的毒理学方案一起成为临床评估用的放射性药物,其生产符合静脉(IV)注射用药物的监管要求。